Shefali Chopra
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Shefali Chopra has a total of 95 co-authors. Here are the top co-authors by number of shared publications:
- Phillip M. Cheng
Department of Radiology, Keck School of Medicine of the University of Southern California, Los Angeles, CA
3 shared publications - Jeffrey A. Kahn
Department of Medicine, Keck School of Medicine of the University of Southern California, Los Angeles, CA
2 shared publications - Justin Lee
Department of Radiology, Keck School of Medicine of USC, Los Angeles, USA
2 shared publications - Kevin G. King
David Geffen School of Medicine at UCLA, Los Angeles, CA
2 shared publications - Navpreet Kaur
Department of Surgery, Keck School of Medicine of the University of Southern California, Los Angeles, CA
2 shared publications Nolan Maloney
The University of Texas MD Anderson Cancer Center, Houston, USA
2 shared publications
Latest Publications
- Open Access
- 1 April 2026
- Published by Wolters Kluwer Health in ACG Case Reports Journal
- Vol. 13 (4)
Liver Transplantation After Prolonged Nab-Sirolimus Therapy for Unresectable Hepatic Perivascular Epithelioid Cell Tumor With Bilobar Involvement
Primary hepatic perivascular epithelioid cell tumor (PEComa) is rare, and management of unresectable disease is not established. A 47-year-old woman had an 8-cm central hepatic PEComa bridging both lobes with tuberous sclerosis complex 2 alterations. She received albumin-bound sirolimus for 26 months with modest size reduction but durable stability, enabling listing with a nonstandard model for end-stage liver disease exception. She underwent right trisegment orthotopic liver transplantation, and the explant showed a well-circumscribed PEComa without vascular invasion or additional lesions. This case highlights prolonged nab-sirolimus as a bridge to transplantation in selected patients with favorable tumor biology.
- 1 April 2026
- Published by Wolters Kluwer Health in ACG Case Reports Journal
- Vol. 13 (4)
Open AccessLiver Transplantation After Prolonged Nab-Sirolimus Therapy for Unresectable Hepatic Perivascular Epithelioid Cell Tumor With Bilobar Involvement
Primary hepatic perivascular epithelioid cell tumor (PEComa) is rare, and management of unresectable disease is not established. A 47-year-old woman had an 8-cm central hepatic PEComa bridging both lobes with tuberous sclerosis complex 2 alterations. She received albumin-bound sirolimus for 26 months with modest size reduction but durable stability, enabling listing with a nonstandard model for end-stage liver disease exception. She underwent right trisegment orthotopic liver transplantation, and the explant showed a well-circumscribed PEComa without vascular invasion or additional lesions. This case highlights prolonged nab-sirolimus as a bridge to transplantation in selected patients with favorable tumor biology.
- Open Access
- 1 December 2025
- Published by Wolters Kluwer Health in ACG Case Reports Journal
- Vol. 12 (12) , e01917
Hepatic Steatosis: A Presentation of Cholesteryl Ester Storage Disease
Cholesteryl ester storage disease is a rare genetic disorder caused by mutations in the LIPA gene, resulting in lysosomal acid lipase deficiency, which leads to abnormal accumulation of cholesteryl esters and triglycerides within lysosomes. We describe a case of late-onset cholesteryl ester storage disease in a woman with elevated liver enzymes, histologic evidence of microvesicular steatosis and cirrhosis, with a confirmed LIPA mutation, who initiated enzyme replacement therapy with sebelipase alfa. This case highlights the importance of considering hereditary disorders of lipid metabolism in patients presenting unexpectedly with steatotic liver disease in the absence of significant metabolic risk factors.
- 1 December 2025
- Published by Wolters Kluwer Health in ACG Case Reports Journal
- Vol. 12 (12) , e01917
Open AccessHepatic Steatosis: A Presentation of Cholesteryl Ester Storage Disease
Cholesteryl ester storage disease is a rare genetic disorder caused by mutations in the LIPA gene, resulting in lysosomal acid lipase deficiency, which leads to abnormal accumulation of cholesteryl esters and triglycerides within lysosomes. We describe a case of late-onset cholesteryl ester storage disease in a woman with elevated liver enzymes, histologic evidence of microvesicular steatosis and cirrhosis, with a confirmed LIPA mutation, who initiated enzyme replacement therapy with sebelipase alfa. This case highlights the importance of considering hereditary disorders of lipid metabolism in patients presenting unexpectedly with steatotic liver disease in the absence of significant metabolic risk factors.
- 7 April 2025
- Published by Wolters Kluwer Health in Advances in Anatomic Pathology
Preneoplastic and Neoplastic Biliary Diseases
Preneoplastic and neoplastic biliary disease comprises biliary intraepithelial neoplasia (BilIN), intraductal papillary neoplasms, mucinous cystic neoplasms (MCNs), and cholangiocarcinoma and their variants. Correct recognition of these entities can be challenging, especially on small/needle biopsies, but is required to plan therapy and guide transplant in the setting of cirrhosis. Salient histologic features of these entities, along with ancillary use of immunostains and key molecular findings aiding in diagnosis, are discussed. Type 2 intraductal papillary neoplasm of the bile ducts is typically associated with an invasive malignancy and lack unique molecular features associated with the Type 1 intraductal papillary neoplasm, thus they are called “papillary cholangiocarcinoma” by some authors. Some of the cholangiocarcinoma variants, like enteroblastic and mucoepidermoid, are under-recognized and can pose diagnostic challenges. The tubulocystic and cholangioblastic variants are relatively recently described but are being increasingly recognized. The cholangioblastic variant has a novel NIBPL-NACC1 fusion described in the more recent larger series reported, making it a somewhat unique variant of cholangiocarcinoma. Nomenclature of the cholangioblastic variant is in evolution as is the link between adenofibroma and the tubulocystic variant. Correct recognition of these variant subtypes would aid in long-term studies to better determine the prognosis in these subtypes.
- 7 April 2025
- Published by Wolters Kluwer Health in Advances in Anatomic Pathology
Preneoplastic and Neoplastic Biliary Diseases
Preneoplastic and neoplastic biliary disease comprises biliary intraepithelial neoplasia (BilIN), intraductal papillary neoplasms, mucinous cystic neoplasms (MCNs), and cholangiocarcinoma and their variants. Correct recognition of these entities can be challenging, especially on small/needle biopsies, but is required to plan therapy and guide transplant in the setting of cirrhosis. Salient histologic features of these entities, along with ancillary use of immunostains and key molecular findings aiding in diagnosis, are discussed. Type 2 intraductal papillary neoplasm of the bile ducts is typically associated with an invasive malignancy and lack unique molecular features associated with the Type 1 intraductal papillary neoplasm, thus they are called “papillary cholangiocarcinoma” by some authors. Some of the cholangiocarcinoma variants, like enteroblastic and mucoepidermoid, are under-recognized and can pose diagnostic challenges. The tubulocystic and cholangioblastic variants are relatively recently described but are being increasingly recognized. The cholangioblastic variant has a novel NIBPL-NACC1 fusion described in the more recent larger series reported, making it a somewhat unique variant of cholangiocarcinoma. Nomenclature of the cholangioblastic variant is in evolution as is the link between adenofibroma and the tubulocystic variant. Correct recognition of these variant subtypes would aid in long-term studies to better determine the prognosis in these subtypes.
- Open Access
- 7 March 2025
- Published by Elsevier in JHEP Reports
- Vol. 7 (6) , 101385
Proinflammatory macrophages release CXCL5 to regulate T cell function and limit effects of αPD-1 in steatosis-driven liver cancer
- 7 March 2025
- Published by Elsevier in JHEP Reports
- Vol. 7 (6) , 101385
Open AccessProinflammatory macrophages release CXCL5 to regulate T cell function and limit effects of αPD-1 in steatosis-driven liver cancer
- 8 January 2025
- Published by Wiley in Diagnostic Cytopathology
- Vol. 53 (3) , 139-145
Serous Cystadenoma of the Pancreas: An Easily Missed Cytological Diagnosis and Clues to Diagnosis
Serous cystadenoma (SCA) of the pancreas is a benign nonmucinous cystic pancreatic neoplasm and the second most common type of pancreatic cystic neoplasm. Conservative management is advocated in asymptomatic cases as they have indolent clinical behavior and risk for postoperative morbidity, making an exact diagnosis essential. Morphologically, serous cystadenoma has a prominent subepithelial capillary meshwork causing the aspirate to be paucicellular and nondiagnostic. Therefore, cytologic diagnosis can be challenging, resulting in repeat aspirations or even unnecessary surgical resections. Since this is a diagnosis that is often overlooked, herein we offer a concise review of SCA along with characteristic radiology findings, diagnostic criteria including ancillary studies and possible differential considerations.
- 8 January 2025
- Published by Wiley in Diagnostic Cytopathology
- Vol. 53 (3) , 139-145
Serous Cystadenoma of the Pancreas: An Easily Missed Cytological Diagnosis and Clues to Diagnosis
Serous cystadenoma (SCA) of the pancreas is a benign nonmucinous cystic pancreatic neoplasm and the second most common type of pancreatic cystic neoplasm. Conservative management is advocated in asymptomatic cases as they have indolent clinical behavior and risk for postoperative morbidity, making an exact diagnosis essential. Morphologically, serous cystadenoma has a prominent subepithelial capillary meshwork causing the aspirate to be paucicellular and nondiagnostic. Therefore, cytologic diagnosis can be challenging, resulting in repeat aspirations or even unnecessary surgical resections. Since this is a diagnosis that is often overlooked, herein we offer a concise review of SCA along with characteristic radiology findings, diagnostic criteria including ancillary studies and possible differential considerations.
- 12 June 2024
- Published by Elsevier in Metabolism
- Vol. 159, 155942
The mitochondrial TSPO ligand Atriol mitigates metabolic-associated steatohepatitis by downregulating CXCL1
- 12 June 2024
- Published by Elsevier in Metabolism
- Vol. 159, 155942
The mitochondrial TSPO ligand Atriol mitigates metabolic-associated steatohepatitis by downregulating CXCL1
- Open Access
- 16 May 2024
- Published by MDPI AG in Biomedicines
- Vol. 12 (5) , 1105
Circulating Neutrophil Profiles Undergo a Dynamic Shift during Metabolic Dysfunction-Associated Steatohepatitis (MASH) Progression
Neutrophils play a crucial role in host defense against infection. Aberrant neutrophil activation may induce tissue damage via sterile inflammation. Neutrophil accumulation has been identified as a feature of the inflammatory response observed in metabolic dysfunction-associated steatohepatitis (MASH) and has been associated with liver fibrosis and cirrhosis. Here, we performed the transcriptomic analysis of circulating neutrophils from mild and advanced MASH patients to identify the potential mechanism behind neutrophil contribution to MASH progression. Our findings demonstrated that circulating neutrophils from mild and advanced MASH display an increased activated transcriptional program, with the expression of pro-inflammatory factors and an amplified lifespan compared to cells from non-diseased controls. Our results also suggest that MASH progression is associated with a dynamic shift in the profile of circulating neutrophils. In the early stages of MASH, mature neutrophils predominate in the bloodstream. As hepatic inflammation and fibrosis progress, the premature release of immature neutrophils into the circulation occurs. These immature neutrophils exhibit a pro-inflammatory profile that may exacerbate inflammation and promote fibrosis in MASH.
- 16 May 2024
- Published by MDPI AG in Biomedicines
- Vol. 12 (5) , 1105
Open AccessCirculating Neutrophil Profiles Undergo a Dynamic Shift during Metabolic Dysfunction-Associated Steatohepatitis (MASH) Progression
Neutrophils play a crucial role in host defense against infection. Aberrant neutrophil activation may induce tissue damage via sterile inflammation. Neutrophil accumulation has been identified as a feature of the inflammatory response observed in metabolic dysfunction-associated steatohepatitis (MASH) and has been associated with liver fibrosis and cirrhosis. Here, we performed the transcriptomic analysis of circulating neutrophils from mild and advanced MASH patients to identify the potential mechanism behind neutrophil contribution to MASH progression. Our findings demonstrated that circulating neutrophils from mild and advanced MASH display an increased activated transcriptional program, with the expression of pro-inflammatory factors and an amplified lifespan compared to cells from non-diseased controls. Our results also suggest that MASH progression is associated with a dynamic shift in the profile of circulating neutrophils. In the early stages of MASH, mature neutrophils predominate in the bloodstream. As hepatic inflammation and fibrosis progress, the premature release of immature neutrophils into the circulation occurs. These immature neutrophils exhibit a pro-inflammatory profile that may exacerbate inflammation and promote fibrosis in MASH.
- Open Access
- 1 April 2024
- Published by Wolters Kluwer Health in ACG Case Reports Journal
- Vol. 11 (4) , e01307
Benign to Malignant Hepatic Lesion Transformation in Abernethy Malformation
Malignant liver tumors, and hepatopulmonary syndrome. We describe a case where a female adult diagnosed with congenital extrahepatic portosystemic shunt subsequently developed focal nodular hyperplasia and then hepatocellular carcinoma....
- 1 April 2024
- Published by Wolters Kluwer Health in ACG Case Reports Journal
- Vol. 11 (4) , e01307
Open AccessBenign to Malignant Hepatic Lesion Transformation in Abernethy Malformation
Malignant liver tumors, and hepatopulmonary syndrome. We describe a case where a female adult diagnosed with congenital extrahepatic portosystemic shunt subsequently developed focal nodular hyperplasia and then hepatocellular carcinoma....
- 20 November 2023
- Published by Elsevier in Human Pathology
- Vol. 143, 1-4
CSF1 expression in xanthogranulomatous epithelial tumor/keratin-positive giant cell-rich tumor
- 20 November 2023
- Published by Elsevier in Human Pathology
- Vol. 143, 1-4
CSF1 expression in xanthogranulomatous epithelial tumor/keratin-positive giant cell-rich tumor
- 2 June 2023
- Published by Wolters Kluwer Health in Advances in Anatomic Pathology
- Vol. 30 (5) , 307-319
Pathologic Diagnosis of Well-differentiated Hepatocellular Lesions: A Practical Approach to Diagnosis With Particular Focus in Core Needle Biopsies and Utilization of Ancillary Techniques
Common well-differentiated hepatocellular lesions include focal nodular hyperplasia, focal nodular hyperplasia–like lesions, large regenerative nodule, hepatocellular adenoma, dysplastic nodule, and hepatocellular carcinoma. The term atypical hepatocellular neoplasm/hepatocellular neoplasm of uncertain malignant potential can be used especially in needle core biopsies when a well-differentiated hepatocellular lesion is either histologically atypical (focal reticulin loss, focal cytologic/architectural atypia) or is clinically atypical (male sex or female >50 y) and cannot be confidently classified as adenoma or hepatocellular carcinoma. These are resected in an attempt for more definite classification. Although radiology can suggest the diagnosis in some of the entities mentioned above, needle core biopsies are often performed to confirm the diagnosis and plan therapy. Diagnosis of these lesions on needle core biopsies can be challenging and may have overlapping histologic and sometimes even immunohistochemical features. Herein, we review the histologic, immunohistochemical, and molecular features of well-differentiated hepatocellular lesions, along with recent advances in this area. We also provide the best approach for the diagnosis of well-differentiated hepatocellular lesions with ancillary testing, especially on needle core biopsies, and discuss the pitfalls. Accurate recognition of well-differentiated hepatocellular lesions is essential as some of them have excellent prognosis and may not require resection, while others have histologic prognostic information that is key for management.
- 2 June 2023
- Published by Wolters Kluwer Health in Advances in Anatomic Pathology
- Vol. 30 (5) , 307-319
Pathologic Diagnosis of Well-differentiated Hepatocellular Lesions: A Practical Approach to Diagnosis With Particular Focus in Core Needle Biopsies and Utilization of Ancillary Techniques
Common well-differentiated hepatocellular lesions include focal nodular hyperplasia, focal nodular hyperplasia–like lesions, large regenerative nodule, hepatocellular adenoma, dysplastic nodule, and hepatocellular carcinoma. The term atypical hepatocellular neoplasm/hepatocellular neoplasm of uncertain malignant potential can be used especially in needle core biopsies when a well-differentiated hepatocellular lesion is either histologically atypical (focal reticulin loss, focal cytologic/architectural atypia) or is clinically atypical (male sex or female >50 y) and cannot be confidently classified as adenoma or hepatocellular carcinoma. These are resected in an attempt for more definite classification. Although radiology can suggest the diagnosis in some of the entities mentioned above, needle core biopsies are often performed to confirm the diagnosis and plan therapy. Diagnosis of these lesions on needle core biopsies can be challenging and may have overlapping histologic and sometimes even immunohistochemical features. Herein, we review the histologic, immunohistochemical, and molecular features of well-differentiated hepatocellular lesions, along with recent advances in this area. We also provide the best approach for the diagnosis of well-differentiated hepatocellular lesions with ancillary testing, especially on needle core biopsies, and discuss the pitfalls. Accurate recognition of well-differentiated hepatocellular lesions is essential as some of them have excellent prognosis and may not require resection, while others have histologic prognostic information that is key for management.